Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Life Sciences Tools & Services · CIK 0001478242
$276.63
+3.28% · delayed ~15 min
Last price from Oct 21, 2026
$46.92B market value
From IQVIA HOLDINGS INC.'s FY2025 10-K, filed Feb 17, 2026 · read the filing
IQVIA provides engineering, research and consulting services. It took in $16.31B last year, which makes it a large company. Of every dollar it sells, about 8 cents is left as profit.
The financial picture is mixed, with profitability, growth and debt needing attention.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Recent open-market selling by 6 insiders, not under a pre-arranged plan.
$29.9M sold in the last 120 days · Read the filing
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
A mixed picture — some clear strengths and some weaknesses.
From IQVIA HOLDINGS INC.'s FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Cash
$1.70B → $1.98B
Revenue
$15.40B → $16.31B
Gross margin
34.9% → 33.3%
Long-term debt
$12.84B → $13.88B
Measured against FY2024, from the 10-K filed Feb 17, 2026
Improved: +16.3%
$1.70B to $1.98BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
How the latest move compares (quote delayed ~15 min), and what was published around it
IQV rose 3.28% on the latest quote. The average Health Care company tracked here moved +1.64%, and the S&P 500 −1.04%. That is 1.6 points above its sector and 4.3 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 11% a year for the next 10 years. Over the last 10 years it grew by about 18% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 8 cents of every dollar of sales as profit, earning $1.36B last year.
Slowly. Sales grew 5.9% last year.
Manageable, but notable. Clearing its debt would take about 5.2 years of cash flow. For every $1 it owes, it owns $1.28 in assets.
Core operating and valuation reference metrics
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it earned $1.36B and generated $2.65B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 17, 2026Filing for FY2025 | FY202410-K · Feb 17, 2026Filing for FY2024 | FY202310-K · Feb 15, 2024Filing for FY2023 | FY202210-K · Feb 15, 2023Filing for FY2022 | FY202110-K · Feb 16, 2022Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $16.31B | $15.40B | $14.98B | $14.41B | $13.87B | +5.9% |
| Cost of revenue | $10.88B | $10.03B | $9.74B | $9.38B | $9.23B | +8.5% |
| Gross profit | $5.43B† | $5.38B† | $5.24B† | $5.03B† | $4.64B† | +1.0% |
| Gross marginGross profit ÷ revenueWhat is this? | 33.3% | 34.9% | 35.0% | 34.9% | 33.5% | −1.6 pts |
| Selling, general and administrative | $2.00B | $1.99B | $2.05B | $2.07B | $1.96B | +0.4% |
| Operating income | $2.18B | $2.20B | $1.98B | $1.80B | $1.39B | −0.9% |
| Operating marginOperating income ÷ revenueWhat is this? | 13.4% | 14.3% | 13.2% | 12.5% | 10.0% | −0.9 pts |
| Interest expense | $729.0M | $670.0M | $672.0M | $416.0M | $375.0M | +8.8% |
| Income before tax | $1.59B | $1.67B | $1.46B | $1.36B | $1.13B | −4.7% |
| Net income | $1.36B | $1.37B | $1.36B | $1.09B | $966.0M | −0.9% |
| Net marginNet income ÷ revenueWhat is this? | 8.3% | 8.9% | 9.1% | 7.6% | 7.0% | −0.6 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $8.02 | $7.80 | $7.48 | $5.88 | $5.07 | +2.8% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| IQVIQVIA HOLDINGS INC. · this page | 6.0/10 | 5/9 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Exercised stock options — 5,381 shares at $131.82 ($709.3K)
Holds 13,558 shares after this filing.
Sold on the open market — 2,668 shares at $261.33 ($697.2K)
Holds 10,890 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Signed a material agreement · Took on a direct financial obligation
Read the filingReported another event
Read the filingWrite down why you are following IQVIA HOLDINGS INC., what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 431 subsidiaries named in its 10-K, incorporated across 103 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from IQV's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 17, 2026), reported under the US GAAP taxonomy. View the source filing.
3 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. Accounting had too few reported figures and is left out of the average rather than counted as a weakness, so a company is never marked down for a figure it did not publish. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 6.0 | 5/9 | 10-K, filed Feb 17, 2026 |
| FY2024 | 6.0 | 7/9 | 10-K, filed Feb 13, 2025 |
| FY2023 | 6.0 | 7/9 | 10-K, filed Feb 15, 2024 |
| FY2022 | 4.7 | 7/9 | 10-K, filed Feb 15, 2023 |
| FY2021 | 6.0 | 7/9 | 10-K, filed Feb 16, 2022 |
| FY2020 | 4.7 | 6/9 | 10-K, filed Feb 12, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
5 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
1.13
In the grey zone
For this model, above 2.6 is safe and below 1.1 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — This company has not reported enough of the required figures to calculate this score.
This company has not reported enough of the required figures to calculate this score.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +5.9%
$15.40B to $16.31BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Deteriorated: −1.6 pts
34.9% to 33.3%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Deteriorated: +8.1%
$12.84B to $13.88BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Improved: -3.7%
176.1M to 169.6MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Q1 FY2026 against Q1 FY2025, from the 10-Q filed May 5, 2026 — read it.
Improved: +15.3%
$426.0M to $491.0MSignificant
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Improved: +8.4%
$3.83B to $4.15BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +10.0%
$249.0M to $274.0MNotable
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: −1.3 pts
33.9% to 32.6%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: +14.8%
$1.43 to $1.64Notable
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: +6.7%
$13.11B to $13.99BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Improved: +11.9%
$1.74B to $1.95BNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: -4.1%
174.1M to 166.9MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Changed: -10.6%
$142.0M to $127.0MNotable
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
8 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 8% and 13%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 27 analysts covering this company, as of . Their views, not this site's.
Of 27 analysts publishing on this company, 9 say strong buy, 14 say buy and 4 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 1.9% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 41.9x — a high multiple relative to the current trailing profit.
This company has not reported enough of the required figures to calculate this score.
| 5.9% |
| 8.3% |
| 34.50x |
| 3.59x |
| TMOTHERMO FISHER SCIENTIFIC INC. | 7.3/10 | 6/8 | 3.9% | 15.0% | 38.07x | 1.07x |
|---|
| DHRDANAHER CORP /DE/ | 9.0/10 | 5/9 | 2.9% | 14.7% | 44.94x | 0.59x |
|---|
| AAGILENT TECHNOLOGIES, INC. | 9.0/10 | 6/9 | 6.7% | 18.8% | 37.77x | 0.89x |
|---|
| WATWATERS CORP /DE/ | 9.0/10 | 6/9 | 7.0% | 20.3% | 42.22x | 0.98x |
|---|
| MTDMETTLER TOLEDO INTERNATIONAL INC/ | 8.7/10 | 7/9 | 4.0% | 21.6% | 39.46x | -158.08x |
|---|
| Median of peers | 9.0/10 | — | 4.0% | 18.8% | 39.46x | 0.89x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Shares were sold back to the company — 2,713 shares at $261.54 ($709.6K)
Holds 8,177 shares after this filing.
Sold on the open market — 1,855 shares at $235.27 ($436.4K)
Holds 1,348 shares after this filing.
Sold on the open market — 5,500 shares at $232.68 ($1.3M)
Holds 13,312 shares after this filing.
Exercised stock options — 156,206 shares at $78.21 ($12.2M)
Holds 992,147 shares after this filing.
Sold on the open market — 4,465 shares at $247.10 ($1.1M)
Holds 987,682 shares after this filing.
Sold on the open market — 4,584 shares at $246.85 ($1.1M)
Holds 983,098 shares after this filing.
Sold on the open market — 44,039 shares at $246.08 ($10.8M)
Holds 939,059 shares after this filing.
Sold on the open market — 53,191 shares at $244.78 ($13.0M)
Holds 885,868 shares after this filing.
Shares were sold back to the company — 47,858 shares at $244.60 ($11.7M)
Holds 838,010 shares after this filing.
Shares were sold back to the company — 2,069 shares at $247.00 ($511.0K)
Holds 835,941 shares after this filing.
Sold on the open market — 558 shares at $245.21 ($136.8K)
Holds 2,989 shares after this filing.
Sold on the open market — 5,000 shares at $249.16 ($1.2M)
Holds 20,999 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 2,668 shares ($697.2K) on or after .
Shares originally obtained via Stock Appreciation Rights.
Filed notice to sell 5,500 shares ($1.3M) on or after .
Shares originally obtained via Restricted Stock.
Filed notice to sell 1,855 shares ($436.4K) on or after .
Shares originally obtained via Performance Shares.
Filed notice to sell 106,279 shares ($26.1M) on or after .
Shares originally obtained via Stock Appreciation Rights.
Filed notice to sell 5,000 shares ($1.2M) on or after .
Shares originally obtained via Performance Shares.
Filed notice to sell 558 shares ($136.8K) on or after .
Shares originally obtained via Restricted Stock.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Quarterly report on Form 10-Q
Published results
Read the filingSigned a material agreement · Took on a direct financial obligation
Read the filingReported another event
Read the filingReported another event
Read the filingReported another event
Read the filingQuarterly report for Q1 FY2026
Revenue +8.4% · Free cash flow +15.3% · Profit +10.0% — against Q1 FY2025
Read the filingPublished results
Read the filingHad a director or senior officer leave or join · Held a shareholder vote
Read the filingProxy statement for a shareholder meeting
Read the filingAnnual report for FY2025
Revenue +5.9% · Cash +16.3% · Gross margin −1.6 pts — against FY2024
Read the filingPublished results
Read the filingSigned a material agreement · Took on a direct financial obligation
Read the filingHad a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingQuarterly report for Q3 FY2025
Revenue +5.2% · Gross profit +50.1% · Gross margin +10.0 pts — against Q3 FY2024
Read the filingPublished results
Read the filingHad a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingQuarterly report for Q2 FY2025
Revenue +5.3% · Operating margin −1.0 pts · Gross profit +53.3% — against Q2 FY2024
Read the filingThe first 40 of 431. The rest are in the exhibit.
Source: Exhibit 21 of the 10-K filed 2026-02-17. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
IQVIA Gears Up to Post Q3 Earnings: Here's What Investors Should Know
Yahoo Finance ·
IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?
Yahoo Finance ·
1 Large-Cap Stock to Research Further and 2 We Avoid
Yahoo Finance ·
IQVIA Holdings (IQV) Gains as Improving Demand Environment and High Win Rates
Yahoo Finance ·
IQVIA Holdings’ Quarterly Earnings Preview: What You Need to Know
Yahoo Finance ·
IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes
Yahoo Finance ·
IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions
Yahoo Finance ·
IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026
Yahoo Finance ·
IQVIA Holdings (IQV) Prices $2b Notes, Does The Stock Look Fairly Valued?
Yahoo Finance ·
IQVIA Selects Veeva Clinical Operations Applications
Yahoo Finance ·
Is Veeva Systems Stock Really Expensive?
Yahoo Finance ·
AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth
Yahoo Finance ·
Primary sources and further research